Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model

BACKGROUND: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Hua-Hao, Wang, Li-Qin, Liu, Wen-Li, An, Xiao-Ping, Liu, Zhen-Dong, He, Xiao-Qi, Song, Li-Hua, Tong, Yi-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147283/
https://www.ncbi.nlm.nih.gov/pubmed/32149769
http://dx.doi.org/10.1097/CM9.0000000000000797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147283/
https://www.ncbi.nlm.nih.gov/pubmed/32149769
http://dx.doi.org/10.1097/CM9.0000000000000797

Ejemplares similares